-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Inflammation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Inflammation Drug Details: DFV-890 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Familial Cold Autoinflammatory Syndrome...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Coronary Artery Disease (CAD) (Ischemic Heart Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Coronary Artery Disease (CAD) (Ischemic Heart Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Coronary Artery Disease (CAD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-500 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TAK-500 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TAK-500 in Non-Small Cell Lung Cancer Drug Details: TAK-500...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DFV-890 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DFV-890 in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DFV-890 in Myelodysplastic Syndrome Drug Details: DFV-890 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LYL-845 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LYL-845 in Metastatic Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LYL-845 in Metastatic Melanoma Drug Details: LYL-845 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bupivacaine in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bupivacaine in Post-Operative Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bupivacaine in Post-Operative Pain Drug Details: Bupivacaine (ATX-101) is under development...
-
Product Insights
Net Present Value Model: DFV-890
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model DFV-890 Drug Details DFV-890 is under...